These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33814357)

  • 1. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
    Algarni AS; Ram-Wolff C; Bagot M; De Masson A
    Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
    Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
    Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.
    Ricci C; Pileri A; Agostinelli C; Ambrosi F; Zinzani PL; Sabattini E
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1263-1265. PubMed ID: 30277017
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
    Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
    Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Persistent Effects of Mogamulizumab on Peripheral Blood Lesions after Treatment Completion in a Patient with Refractory Sézary Syndrome-A Case Report].
    Manabe M; Endo H; Inano N; Hagiwara Y; Nanno S; Koh KR
    Gan To Kagaku Ryoho; 2024 Aug; 51(8):833-835. PubMed ID: 39191715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
    Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation.
    Trotta GE; Ciangola G; Cerroni I; Mezzanotte V; Nunzi A; Anemona L; Savino L; De Angelis G; Mariotti B; Bonanni F; Meddi E; Zizzari A; Rapisarda VM; Mangione I; Bruno A; Cantonetti M; Venditti A; Cerretti R
    Curr Res Transl Med; 2024 Sep; 72(3):103452. PubMed ID: 38718540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
    Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
    Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mogamulizumab for Sézary syndrome: long-term remission with associated autoimmune haemolytic anaemia.
    Lé AM; Peixeiro R; Lau C; Teixeira MDA; Cabral R; Fernandes I
    Eur J Dermatol; 2024 Aug; 34(4):457-459. PubMed ID: 39193694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.